ArticleIJU case reports2026
Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Avelumab maintenance after response to platinum chemotherapy improves outcomes in metastatic urothelial carcinoma. Progression during maintenance presents a therapeutic dilemma. Case Presentation: A 72-year-old man underwent radical cystectomy and left nephroureterectomy for high-grade urothelial carcinoma. Two and a half years later, a solitary pelvic nodal recurrence achieved complete response to gemcitabine-cisplatin, after which avelumab maintenance was started. After 16 cycles, the same node regrew, indicating progression. Pembrolizumab was initiated and induced a second complete response after four cycles. He remains recurrence-free for three years without immune-related adverse events. Conclusion: Durable remission with pembrolizumab following progression on avelumab suggests that switching from PD-L1 to PD-1 blockade can overcome resistance in selected patients; prospective studies and biomarker strategies, including PD-L2 assessment, are warranted and may guide individualized rechallenge strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.